ATE311186T1 - Verwendung von vitamin pp verbindungen - Google Patents

Verwendung von vitamin pp verbindungen

Info

Publication number
ATE311186T1
ATE311186T1 AT99922119T AT99922119T ATE311186T1 AT E311186 T1 ATE311186 T1 AT E311186T1 AT 99922119 T AT99922119 T AT 99922119T AT 99922119 T AT99922119 T AT 99922119T AT E311186 T1 ATE311186 T1 AT E311186T1
Authority
AT
Austria
Prior art keywords
compounds
vitamin
pellagra
activity
formula
Prior art date
Application number
AT99922119T
Other languages
German (de)
English (en)
Inventor
Elfi Biedermann
Max Hasmann
Roland Loeser
Benno Rattel
Friedemann Reiter
Barbara Schein
Isabel Schemainda
Klaus Seibel
Klaus Vogt
Katja Wosikowski
Original Assignee
Klinge Co Chem Pharm Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinge Co Chem Pharm Fab filed Critical Klinge Co Chem Pharm Fab
Application granted granted Critical
Publication of ATE311186T1 publication Critical patent/ATE311186T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99922119T 1998-04-22 1999-04-21 Verwendung von vitamin pp verbindungen ATE311186T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19818044A DE19818044A1 (de) 1998-04-22 1998-04-22 Verwendung von Vitamin-PP-Verbindungen
PCT/EP1999/002686 WO1999053920A1 (en) 1998-04-22 1999-04-21 Use of vitamin pp compounds

Publications (1)

Publication Number Publication Date
ATE311186T1 true ATE311186T1 (de) 2005-12-15

Family

ID=7865483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922119T ATE311186T1 (de) 1998-04-22 1999-04-21 Verwendung von vitamin pp verbindungen

Country Status (9)

Country Link
US (1) US20100227896A1 (enExample)
EP (1) EP1079832B1 (enExample)
JP (1) JP4607319B2 (enExample)
AT (1) ATE311186T1 (enExample)
AU (1) AU3928299A (enExample)
DE (2) DE19818044A1 (enExample)
DK (1) DK1079832T3 (enExample)
ES (1) ES2253890T3 (enExample)
WO (1) WO1999053920A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
GB0104240D0 (en) 2001-02-21 2001-04-11 Clariant Int Ltd Copolymer composition having pigment like properties
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US8211912B2 (en) * 2007-09-26 2012-07-03 Gemin X Pharmaceuticals Canada Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor
EP2213288A1 (en) * 2009-01-30 2010-08-04 Karl Welte NAMPT and vitamin B3 for treating or preventing diseases
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US9889222B2 (en) 2011-11-09 2018-02-13 Kimberly-Clark Worldwide, Inc. Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness
US8791045B2 (en) 2011-11-09 2014-07-29 Kimberly-Clark Worldwide, Inc. Non-tacky wetness indicator composition for application on a polymeric substrate
US9585826B2 (en) 2012-11-07 2017-03-07 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of active chemistry
US9938258B2 (en) 2012-11-29 2018-04-10 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
US9856241B2 (en) 2013-07-03 2018-01-02 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
WO2015042414A1 (en) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
US9119780B2 (en) 2013-10-30 2015-09-01 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of proactive chemistry
JP2018528196A (ja) 2015-08-18 2018-09-27 カリオファーム セラピューティクス,インコーポレイテッド 癌の治療のための(s,e)−3−(6−アミノピリジン−3−イル)−n−((5−(4−(3−フルオロ−3−メチルピロリジン−1−カルボニル)フェニル)−7−(4−フルオロフェニル)ベンゾフラン−2−イル)メチル)アクリルアミド
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
RU2651047C1 (ru) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственная композиция цитопротекторного действия и способ ее получения
EP3749306B1 (en) 2018-02-05 2025-09-03 The Trustees of Indiana University Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same
CN115177594B (zh) * 2022-07-04 2023-08-15 武汉大学中南医院 一种阿昔替尼药物制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3148115A (en) * 1958-12-08 1964-09-08 Horner Frank W Ltd Potentiation of tumor-growth inhibition from deoxypyridoxine, testosterone, or 6-mercaptopurine, by 6-aminonicotinamide
JPH04103538A (ja) * 1990-08-24 1992-04-06 Ajinomoto Co Inc 制癌剤副作用抑制剤
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
KR100290129B1 (ko) * 1994-08-12 2001-05-15 마이클 바마트 옥시퓨린 누클레오시드로 패혈증 또는 염증성 질병을 치료하는 방법
JPH0881371A (ja) * 1994-09-09 1996-03-26 Suntory Ltd 造血機能亢進剤
EP0800829B2 (en) * 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
JP2860637B2 (ja) * 1995-12-11 1999-02-24 末綱 陽子 新規なペプチドおよび活性化酸素阻害剤
JP3836203B2 (ja) * 1995-12-20 2006-10-25 日本臓器製薬株式会社 活性酸素・フリーラジカル消去剤
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) * 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US6451816B1 (en) * 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624704A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
JPH1045594A (ja) * 1996-07-30 1998-02-17 Mitsubishi Gas Chem Co Inc 活性酸素消去剤

Also Published As

Publication number Publication date
DE69928660D1 (de) 2006-01-05
DE69928660T2 (de) 2006-09-14
EP1079832A1 (en) 2001-03-07
JP2002512190A (ja) 2002-04-23
DE19818044A1 (de) 1999-10-28
AU3928299A (en) 1999-11-08
JP4607319B2 (ja) 2011-01-05
WO1999053920A1 (en) 1999-10-28
ES2253890T3 (es) 2006-06-01
EP1079832B1 (en) 2005-11-30
US20100227896A1 (en) 2010-09-09
DK1079832T3 (da) 2006-04-03

Similar Documents

Publication Publication Date Title
DE69928660D1 (de) Verwendung von vitamin pp verbindungen
MY138897A (en) W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE444752T1 (de) 2-aminopyridin-verbindungen und ihre verwendung als medikamente
DE59810922D1 (de) 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester-transfer-proteins (ctep)
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
BR9705727A (pt) Heterocicilos com anel de cinco membros como inibidores da adesão de leucócitos e como antigonistas de vla-4.
EP1731523A4 (en) THIAZOLOPYRIMIDINDERIVAT
ATE251141T1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
ATE496893T1 (de) Isochinolinonderivate und deren verwendung als medikamente
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
MY137944A (en) Specific glucocorticoid compounds having anti-inflammatory activity
NO971269L (no) 2-aryl-substituerte pyridiner
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
TR199902383T2 (xx) Yeni pirimidin t�revleri ve bunlar�n haz�rlanmas� i�in proses.
NO20060871L (no) Azepinderivater som farmasoytiske midler
ATE515262T1 (de) Verwendung von parthenolid-derivaten als antileukämische und zytotoxische mittel
IE43951L (en) 1-benzazolylalkyl-4-substituted-piperdines
ATE269331T1 (de) Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
AR032185A1 (es) Complejos de cis-platino, utiles como agentes antitumorales, y las composiciones farmaceuticas que los contienen
TR200001452T2 (tr) Bifenilamidin türevleri.
WO2003059907A1 (en) Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
ATE39357T1 (de) Derivate von griseolicsaeure und ihre verwendung.
NO20004273L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende forbindelsene
DE69920455D1 (de) Bis-indolederivate und ihre verwendung als entzündungshemmende mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1079832

Country of ref document: EP

EEIH Change in the person of patent owner
EEIH Change in the person of patent owner